December 01, 2013
4 min read
Save

Pipeline or pipe dream: New antibiotics for 
multidrug-resistant gram-negative bacilli

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Antibiotic resistance is a health care concern that has been recognized since the invention of antibiotics. In 1945, Alexander Fleming himself warned against the overuse of penicillin and asked that it stopped being overprescribed. Yet, even today we continue this same message of stopping the unnecessary use of antibiotics.

In 2009, more than 3 million kg of antibiotics were used in humans, and in 2010, 13 million kg were used in animals. Now, in recent years, antibiotic resistance has gained greater attention on both a national and global scale. Several key organizations, including the CDC, WHO and the Infectious Diseases Society of America, have declared antibiotic resistance a global crisis.

International efforts to confront this public health crisis have been spearheaded by initiatives such as the “10 x ’20 Initiative” launched by the IDSA, and the Generating Antibiotics Incentives Now (GAIN) Act, which was passed by Congress in 2012. The most recent update on the 10 x ’20 Initiative highlighted drugs that are active against multidrug-resistant gram-negative bacilli (MDR-GNB). This update coincides with the release of the CDC report, “Antibiotic Resistance Threats in the United States, 2013,” which characterized the threat level from carbapenem-resistant Enterobacteriaceae (CRE) as urgent, requiring immediate and aggressive action. Unfortunately, data from the IDSA 10 x ‘20 Initiative paints a grim picture of the future of new antibiotic development.

Current state of antibiotic pipeline

According to the most recent update from the IDSA regarding the antibiotic pipeline, there are only seven compounds that target gram-negative pathogens in phase 2 or phase 3 trials (Table 1). Even more concerning is that only three of the compounds could be considered “novel.” The remaining agents in development are new compounds in already established classes.

The novel compounds include the new beta-lactamase inhibitors avibactam (Forest Laboratories) and MK-7655 (Merck), as well as the peptide mimetic brilacidin (Cellceutix). Avibactam is a non-beta-lactam, beta-lactamase inhibitor that is being studied in combination with ceftazidime and ceftaroline (Teflaro, Forest Laboratories). Avibactam is a potent inhibitor of Amber class A and C beta-lactamases, as well as some class D beta-lactamases. Clinically, this translates to an ability to extend coverage to extended-spectrum beta-lactamase (ESBL) and Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. In addition, current pharmacokinetic and safety data suggest that the addition of avibactam does not necessitate dosing changes beyond those of the active drug alone.

Jeff Brock

Gregory Tallman

MK-7655 is another non-beta-lactam, beta-lactamase inhibitor with a similar structure and, therefore, similar spectrum of activity. MK-7655 is currently being studied in combination with imipenem-cilastatin (Primaxin, Merck). Much like avibactam, MK-7655 inhibits class A and C beta-lactamases, broadening antimicrobial coverage to include ESBL- and KPC-producing bacteria. One limitation of both of these new beta-lactamases is that they are only active against certain types of carbenemases (KPCs) and do not extend coverage to metallo-beta-lactamase (NDM-1)-producing bacteria. Despite these limitations, these two new beta-lactamases show promise in extending the utility of existing antibiotics.

Brilacidin is described as a peptide mimetic. It exerts antimicrobial effects by disrupting bacterial membranes. Brilacidin belongs to a new class of antibiotics the manufacturer has dubbed defensin-mimetics. Defensin-mimetics are designed to function similarly to existing host proteins called defensins. This novel mechanism translates to broad gram-positive and gram-negative activity. Current data on brilacidin show activity against ESBLs, and the manufacturer suggests activity against methicillin-resistant Staphylococcus aureus, Enterococcus faecium and NDM-1-producing K. pneumoniae. At this time, there is insufficient data regarding brilacidin’s coverage of Pseudomonas.

In addition, brilacidin has no activity against Acinetobacter baumannii. Recently, a phase 2 trial was completed that compared brilacidin with daptomycin for the treatment of acute bacterial skin and skin structure infections. Brilacidin met all objectives of efficacy and safety in this study. Of note, 65% to 87% of patients in the phase 2 trial experienced adverse events of numbness and tingling. The significance of this is unclear at this time, and the manufacturer is moving forward with a phase 2B study of brilacidin.

Currently, the biggest gap in the investigational pipeline are compounds active against A. baumannii. Unfortunately, despite the advancements that these compounds represent, none of the current agents in the pipeline have significant activity against this troublesome pathogen. Clinicians will have to continue to rely on currently available agents, which can be difficult given the increasing prevalence of MDR Acinetobacter infections.

Future of antibiotic development

The future of treating MDR-GNB is bleak, and a stagnant drug development process is not helping to change that. In further efforts to facilitate the development of antibacterials active against MDR-GNB, the IDSA has recently proposed a new approach to antibacterial drug development called the limited population antibacterial drug (LPAD) approval mechanism. The LPAD mechanism recognizes the unmet need for rapid antibacterial development for serious infections when there are few, if any, therapeutic alternatives.

In this setting, there is greater tolerance for overall drug therapy risk because of the lack of therapeutic options. The LPAD pathway will allow antibacterial drug approval in much smaller, more rapid clinical trials, similar to the Orphan Drug Program. Products approved via LPAD would be subsequently restricted to the indicated population. If approved, this new pathway has potential to facilitate innovation and development of new antibacterials. Until then, we will continue to seek other methods to combat antimicrobial resistance.

During the closing plenary session at ID Week 2013 in October, Brad Spellberg, MD, spoke about the growing crisis of antibiotic resistance. He said the resistance crisis is the predictable result of how we have managed antibiotics during the past 80 years. “If we are to change our present state, we need to challenge assumptions and think disruptively,” he said. He proposed that development and utilization of multiple new antibiotics in the immediate future may not be the best answer to combat antibiotic resistance.

This approach will lead to development of resistance to new antibiotics, and eventually we will be back in the same position as we are today. Instead, a controlled development and release process, coupled with enforcing appropriate use, may help to slow the rate of resistance to existing antimicrobials as well as future compounds. Perhaps novel ways of thinking about antibiotic resistance, coupled with controlled development of novel compounds, will help convert the pipe dream of rapid drug development to a pipeline of sustained research and development of new antibiotics.

References:

Boucher HW. Clin Infect Dis. 2013;56:1685-1694.
Infectious Diseases Society of America. Clin Infect Dis. 2010;50:1081-1083.
Spellberg B. N Engl J Med. 2013;368:299-302.
Zhanel GG. Drugs. 2013;73:159-177.

For more information:

Jeff Brock, PharmD, MBA, is an infectious disease pharmacy specialist at mercy medical center in Des Moines, Iowa. He can be reached at: JBrock@mercydesmoines.org.
Gregory Tallman, PharmD, is a PGY-1 pharmacy practice resident at Mercy Medical Center in Des Moines, Iowa.

Disclosure: Brock and Tallman report no relevant financial disclosures.